Alpha-GPC
L-Alpha glycerylphosphorylcholine
Alpha-GPC (L-alpha glycerylphosphorylcholine, choline alfoscerate) is a choline-containing phospholipid marketed as a nootropic and, in some countries, a prescription drug for cognitive impairment. It is used off-label in the fitness/PED-adjacent space as a purported pre-workout ergogenic and acetylcholine precursor. A very large (~12 million-person) South Korean cohort found alpha-GPC use associated with a significantly higher 10-year stroke risk (both ischemic and hemorrhagic) in a dose-response manner, plausibly via the choline to TMAO pathway; this is the single most important safety signal and it comes from observational data, so causality is not proven but the association is strong and biologically plausible. Efficacy evidence for cognition is mostly in combination with donepezil in older dementia patients; ergogenic/performance evidence in healthy adults comes from small, short, industry-adjacent trials with mixed results. This is not a benign supplement: anyone with cerebrovascular or cardiovascular risk factors should treat the stroke signal seriously and involve a physician.
Mechanism of action
Pharmacokinetics
Not precisely defined for the intact molecule in humans; alpha-GPC is rapidly hydrolyzed and monitored via plasma free choline. After IM administration plasma choline peaks within 0.25-0.5 h and returns toward baseline by ~6 h; after oral dosing the choline signal is slower.
Short; the plasma free-choline rise after a single oral dose peaks at roughly 3.5-3.9 h (Tmax) and is a transient, single-day pharmacologic exposure. Typically dosed one or more times daily in studies.
Oral (soft-gel capsule or film-coated tablet, commonly 400 mg units) and, in older clinical studies, intramuscular injection.
Hydrolyzed to free choline and glycerophosphate; choline is further oxidized/metabolized (including microbiota-dependent conversion to trimethylamine and hepatic conversion to TMAO). Reported for monitoring/washout context only, not for evasion of any testing.
For monitoring and washout planning, not drug-test evasion.
Physiological & performance effects
- Raises plasma free choline after oral or IM dosing (dose-dependent; e.g., substantially elevated 1-2 h post-dose in a healthy-male ergogenic trial).
- In older patients with dementia/cerebrovascular injury, improved or slowed decline in cognitive, functional, and behavioral scores primarily when added to donepezil (combination therapy).
- In small short-term trials of healthy young men, inconsistent ergogenic effects: one crossover trial showed increased isometric lower-body peak force after 6 days; a dose-comparison trial found no benefit on isometric strength or psychomotor vigilance but some change in countermovement-jump velocity/power.
- A combination supplement (BCAAs + L-citrulline + A-GPC) improved cycling peak power and time-to-fatigue, but the design cannot isolate alpha-GPC's contribution.
- Purported subjective focus/alertness effects are not well established by controlled human data.
Adverse effects by system
Most important concern. A large national cohort (~12 million adults >=50 y) associated alpha-GPC use with higher 10-year total, ischemic, and hemorrhagic stroke risk in a dose-response manner (adjusted HR ~1.43 for total stroke). A separate mild-cognitive-impairment cohort reported reduced stroke risk among non-progressors, so the observational data are not fully consistent; causality is unproven but the strong dose-response stroke signal and the plausible choline->TMAO pathway make this a serious flag.
No specific human hepatotoxicity signal identified in the retrieved literature; controlled cognition and ergogenic trials reported good overall tolerability without reported liver injury. Data specifically evaluating liver enzymes are limited/absent, so absence of reported harm is not proof of hepatic safety.
Not a hormonal/androgenic agent; no evidence of gonadal HPTA (testosterone/LH/FSH) suppression. One healthy-male RCT observed significantly depressed serum TSH after 500 mg (thyroid axis, not gonadal), of uncertain clinical significance. Any thyroid or hormonal concerns should be evaluated by an endocrinologist.
No human reproductive or fertility data identified; effects in pregnancy, lactation, and on fertility are unknown and unstudied.
Cholinergic agents can theoretically cause overstimulation; in dementia combination trials, behavioral/apathy scores generally improved rather than worsened. No consistent psychiatric adverse-effect signal in healthy users was identified, but data are limited. Reports of headache, insomnia, or irritability are anecdotal and not well characterized in controlled data.
No renal-specific adverse-effect data identified in the retrieved human literature; effects on kidney function are unstudied/unknown.
No hematologic adverse-effect data identified in the retrieved literature. Any relevance to thrombotic risk would be indirect via the cardiovascular/TMAO pathway rather than a measured hematologic parameter.
No dermatologic adverse effects identified in the retrieved literature; skin reactions are not characterized (data absent).
HPTA suppression & recovery
Suppression: None expected — alpha-GPC is not an androgen, anabolic steroid, or SERM and has no established mechanism for suppressing the gonadal HPTA (testosterone/LH/FSH).
No HPTA recovery protocol is applicable because no gonadal suppression is expected or documented, so SERM therapy is not indicated for this compound; dual-SERM protocols are never appropriate. The only endocrine signal noted in controlled data is transient TSH suppression at 500 mg in one healthy-male trial, involving the thyroid rather than the gonadal axis. Any suspected hormonal or thyroid disturbance should be assessed and managed by an endocrinologist rather than self-treated.
Monitoring
Cadence: Establish a clinician-supervised baseline before starting; reassess cardiovascular/cerebrovascular risk periodically (e.g., annually or per physician), and promptly if any new symptoms arise. There is no validated routine lab specific to alpha-GPC exposure.
- Any signs of stroke — sudden weakness/numbness (especially one-sided), facial droop, slurred speech, sudden severe headache, vision loss, or loss of coordination — call emergency services immediately
- New or worsening chest pain, palpitations, or shortness of breath
- Persistent headache, dizziness, insomnia, or unusual agitation
- Symptoms of thyroid dysfunction (palpitations, heat intolerance, unexplained weight change)
Contraindications
- Prior stroke or transient ischemic attack, or high cerebrovascular risk (given the dose-dependent stroke association in cohort data).
- Established cardiovascular/atherosclerotic disease or multiple cardiovascular risk factors, where a possible choline->TMAO-mediated risk is most concerning.
- Pregnancy and breastfeeding (no human safety data).
- Known hypersensitivity to choline alfoscerate.
- Thyroid disorders or use of thyroid-affecting therapy warrant clinician oversight given the TSH-suppression signal.
- Use alongside cholinergic/anticholinesterase medications should only be under medical supervision.
Interaction profile
- ContraindicatedWith DNP: Additive cardiovascular strain
Check a specific combination in the interaction checker.
Reducing harm & when to stop
- Treat the dose-dependent stroke association seriously: if you have any personal or family history of stroke, TIA, hypertension, atrial fibrillation, or atherosclerotic disease, discuss with a physician before using, and consider avoiding it.
- Clinical dose ranges reported in the literature (cognition: ~1200 mg/day oral or ~1000 mg IM; ergogenic trials: ~300-600 mg/day) are provided only with their risk context — higher/longer choline exposure was associated with greater stroke risk, so more is not better.
- Do not combine with prescription cholinergic/anticholinesterase drugs or manage suspected cognitive decline on your own; that belongs with a physician.
- Stop immediately and seek emergency care for any stroke warning signs (one-sided weakness/numbness, facial droop, slurred speech, sudden severe headache, vision or coordination loss).
- Avoid in pregnancy and breastfeeding due to absent safety data.
- Get baseline cardiovascular risk assessment and blood pressure checked; involve a clinician for periodic monitoring rather than relying on self-assessment.
- Because this compound is not hormonal, do not use SERMs or 'PCT' protocols in connection with it — they are not indicated.
Citations (15)
Every clinical claim above is tied to a primary source. Overall evidence grade B — graded to the best available evidence for its core claims.
- 01
Alpha-GPC (choline alfoscerate) is a choline-containing phospholipid used as a medicine/nutraceutical for cognitive impairment and acts as a cholinergic (acetylcholine) precursor.
Meta-analysisPMID 36683513 ↗
- 02
Alpha-GPC alone or combined with donepezil improved cognition, behavior, and functional outcomes in adult-onset cognitive impairment/cerebrovascular injury (7 RCTs + 1 cohort meta-analyzed).
Meta-analysisDOI 10.3233/JAD-221189 ↗
- 03
Adding choline alphoscerate to donepezil slowed cognitive, functional, and behavioral decline versus donepezil plus placebo over 24 months in Alzheimer's disease with ischemic cerebrovascular injury (ASCOMALVA RCT).
- 04
ASCOMALVA interim (12-month) RCT results: donepezil plus choline alphoscerate improved cognitive/behavioral measures versus donepezil alone.
- 05
Combination of donepezil with choline alphoscerate reduced apathy scores in Alzheimer's disease versus donepezil alone (ASCOMALVA RCT).
- 06
A randomized/open-label trial replicated ASCOMALVA-type benefit: donepezil plus choline alfoscerate gave additional cognitive and noncognitive improvement versus donepezil alone.
- 07
In mild-to-moderate senile dementia of Alzheimer type, alpha-GPC improved most neuropsychological parameters versus acetyl-L-carnitine, with good tolerability.
- 08
In vascular dementia, alpha-GPC (1 g/day IM) showed efficacy with very good tolerability versus CDP-choline.
- 09
After a single 1000 mg IM dose, alpha-GPC produced a rapid rise in plasma free choline peaking at 0.25-0.5 h and declining toward baseline by ~6 h.
- 10
Oral choline alfoscerate 1200 mg pharmacokinetics: plasma choline Tmax ~3.5-3.9 h; both tablet and soft-gel formulations well tolerated with no serious adverse events.
- 11
Alpha-GPC use was associated with higher 10-year total, ischemic, and hemorrhagic stroke risk (adjusted HR ~1.43 total stroke) in a dose-response manner in a ~12 million-person national cohort; choline->TMAO proposed as mechanism.
- 12
In a national MCI cohort, alpha-GPC users had lower risk of progression to Alzheimer's and vascular dementia, and reduced stroke risk among those who did not progress to dementia (mixed cardiovascular signal).
- 13
6 days of 600 mg/day alpha-GPC increased isometric mid-thigh-pull peak force versus placebo in healthy young men (small n=13 crossover RCT).
- 14
7 days of 250/500 mg alpha-GPC raised serum free choline; 500 mg significantly depressed serum TSH; no benefit on isometric strength or psychomotor vigilance, with some change in countermovement-jump velocity/power (n=48 RCT).
- 15
A combination supplement containing 300 mg A-GPC (with BCAAs and L-citrulline) increased cycling peak power and time-to-fatigue versus placebo; alpha-GPC's individual contribution cannot be isolated.
Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice